Alta Partners Investment Strategy and Portfolio Management

Alta Partners is a venture capital firm that has been investing in life sciences and healthcare companies for over 25 years. They have a strong track record of identifying and supporting innovative companies that have the potential to make a significant impact in the industry.

Their investment strategy focuses on making early-stage investments in companies that are developing cutting-edge technologies and treatments. This approach has allowed them to be at the forefront of some of the most exciting developments in the life sciences and healthcare space.

Alta Partners has a diverse portfolio of companies across various therapeutic areas, including oncology, neurology, and infectious disease. They have invested in over 100 companies since their inception, with many of these investments resulting in successful exits and returns.

By focusing on innovative companies and technologies, Alta Partners is able to provide their portfolio companies with the resources and support they need to succeed. This approach has helped their companies to achieve significant milestones and reach new heights in the industry.

For more insights, see: Real Estate Asset Management Companies

Alta Partners has a diverse portfolio of investments, which includes notable companies such as Kite Pharmaceuticals, ZS Pharma, and Esperion.

The firm has a strong focus on the life sciences industry, with investments in companies like DeCode Calistoga and Aerie. This indicates a keen interest in the development of new treatments and technologies.

Alta Partners' investment strategy is supported by its experience in the life sciences industry, which has been honed over its 25+ years of operation.

Intriguing read: Suncorp Group Companies

As you dive into portfolio management, it's essential to understand the service providers involved in your investments.

Alta Partners has a single service provider relationship with Cooley.

Cooley is listed as a counsel service provider.

In this case, Cooley is the only service provider mentioned, and it's associated with Alta Partners as a counsel service provider.

Worth a look: Buy Tecate Alta

Alta Partners has a diverse portfolio with 447 investments, with their latest investment being in Be Biopharma as part of their Series C - II on January 15, 2025.

The firm has a strong presence in the life sciences industry, with 87 investments in this sector alone. They also invest in high tech, healthcare, healthtech, enterprise applications, and others.

Alta Partners has a clear investment strategy, focusing on growth capital and venture investments. They prefer to invest in companies with a strong presence in the East US, Midwest US, South US, West US, United Kingdom, Western Europe, Eastern Europe, and Nordic regions.

The firm typically invests in companies at the Series A, B, C, D, and post-IPO stages, with 45 investments at the Series A stage, 27 at the Series B stage, and 22 at the Series C stage.

Here is a breakdown of the sectors in which Alta Partners invests:

Alta Partners has also co-invested with other investors in 665 portfolio companies over the past 26 years, including funds and angels.

Alta Partners has a significant track record of acquisitions and exits, with 132 portfolio exits and 1 acquisition. Their latest portfolio exit was a merger with BetterVet on October 16, 2024, for an undisclosed valuation.

Alta Partners acquired 1 company, Bioventus, on May 09, 2012, for an undisclosed valuation. This acquisition was a key milestone in their investment portfolio.

Here are some key acquisitions and exits in Alta Partners' portfolio:

Alta Partners has a significant track record of portfolio exits, with a total of 132 exits under their belt.

Their latest portfolio exit was a merger with BetterVet on October 16, 2024. The valuation of this exit is a whopping $XXM.

In addition to mergers, Alta Partners has also facilitated asset sales, such as the sale of Intarcia Therapeutics to i2O Therapeutics on August 30, 2023, also valued at $XXM.

Not all exits are created equal, however. Some, like the acquisition of Affinivax by GSK on May 31, 2022, have been highly successful, with a valuation of $XXM.

Here's a breakdown of some of Alta Partners' notable portfolio exits:

It's worth noting that not all of Alta Partners' portfolio exits have been publicly disclosed, as seen in the IPO and Acq - Pending exits listed above.

Acquisitions are a crucial part of a company's growth strategy, and Alta Partners is no exception. They have made several notable acquisitions, with their latest one being Bioventus on May 09, 2012.

Bioventus was acquired for a valuation of $XXM. This acquisition marks a significant milestone in Alta Partners' history.

Alta Partners' portfolio includes several acquired companies, each with its own unique story. For instance, CymaBay Therapeutics was acquired on February 12, 2024, after being first invested in on November 30, 2004.

The company received a Series C round of investment worth $44M. This is a notable example of Alta Partners' ability to identify and support promising companies.

Here are some key acquisitions made by Alta Partners:

These acquisitions demonstrate Alta Partners' commitment to supporting innovative companies and driving growth in the industry.